+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Motion Sickness Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4896211
  • Report
  • January 2022
  • Region: Global
  • 115 Pages
  • Mordor Intelligence


  • Baxter International Inc
  • Caleb Pharmaceuticals Inc
  • CVS Health
  • GlaxoSmithKline plc
  • Myungmoon Pharm Co. Ltd
  • Perrigo Company plc

The motion sickness treatment market is anticipated to witness a CAGR of nearly 3.0% during the forecast period. There are certain factors that are driving the market growth, including a rise in the number of travelers across the globe and increased incidences of cardiovascular diseases in the geriatric population which majorly cause motion sickness.

For instance, according to United Nations World Tourism Organization (UNWTO), international tourist arrivals increased by 5.4% in 2018 compared to 2017, and this tendency is expected to continue throughout the forecast period which demands higher requirements for motion sickness treatment globally. Also, ongoing research activities in motion sickness drug development and delivery systems are likely to increase the availability of OTC drugs for motion sickness treatment.

Key Market Trends

Anticholinergic Treatment Segment is Expected to Hold the Largest Market Share During the Forecast Period

The anticholinergic treatment segment is expected to account for a significant share of the motion sickness treatment market. The dominance in the revenue share of this segment is due to long-lasting relief, better efficacy, better patient-compliance, and fewer side effects compared to other treatments. Also, the growing demand along with the higher prices of these products is expected to contribute to the highest revenue of the segment during the forecast period.

Next to anticholinergics, the antihistamine treatment segment contributes to the second-highest revenue in the global market. This is due to their access to the patients in a wide range of dosage forms like transdermal patches, oral dosage forms such as chewable tablets, lozenges, etc., as per patient requirement. They are also available as prescriptions and various OTC drugs which are expected to account for their significant growth rate in the motion sickness treatment market.

By the distribution channel, the retail pharmacies segment is expected to have a high revenue share in the market and is expected to continue during the forecast period. The dominance is owing to the higher preference of self-medication and the access to patients which accounts for the significant share in the market.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to account for the largest share of the motion sickness treatment. This is due to increased tourism in the U.S. and preference for highly expensive prescription drugs directly contributes to a significant share of revenue in the region. For instance, according to the UNWTO, in 2018, nearly 52 million International tourists travel from America to Europe resultant in a higher demand for the motion sickness treatment market in the region.

Followed by North America, Europe contributed to the second largest market share owing to a rise in a number of travelers all over the world, increased research activities and investors to develop novel drug delivery systems for motion sickness treatment accounts for the highest revenue.

Competitive Landscape

The motion sickness treatment market is moderately competitive and consists of several major players. Few of the major players currently dominating the market are implementing various development strategies such as making mergers and acquisitions, entering into partnerships and thus, expanding their footprint globally.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Baxter International Inc
  • Caleb Pharmaceuticals Inc
  • CVS Health
  • GlaxoSmithKline plc
  • Myungmoon Pharm Co. Ltd
  • Perrigo Company plc

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increased Number of Travellers and Virtual Reality Exposure Across the Globe
4.2.2 Rise in Adoption of Prescription Motion Sickness Drugs
4.3 Market Restraints
4.3.1 Reluctance in Emerging Countries due to Higher Cost of Prescription Drugs
4.3.2 Excessive Reliance on the OTC and Traditional Medicines
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment Type
5.1.1 Anticholinergics
5.1.2 Antihistamines
5.1.3 Others
5.2 By Distribution Channel
5.2.1 Retail Pharmacies
5.2.2 Online Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 GlaxoSmithKline plc
6.1.2 Perrigo Company plc
6.1.3 Prestige Consumer Healthcare Inc.
6.1.4 WellSpring Pharmaceutical Corporation
6.1.5 Caleb Pharmaceuticals Inc
6.1.6 Myungmoon Pharm Co. Ltd
6.1.7 Baxter International Inc
6.1.8 CVS Health
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • GlaxoSmithKline plc
  • Perrigo Company plc
  • Prestige Consumer Healthcare Inc.
  • WellSpring Pharmaceutical Corporation
  • Caleb Pharmaceuticals Inc
  • Myungmoon Pharm Co. Ltd
  • Baxter International Inc
  • CVS Health
Note: Product cover images may vary from those shown